My interest is in whether Veyonda consistently prevented patients from deteriorating from moderate status. Recognising of course that the focus of the trial was safety, not efficacy.
My interest is in whether Veyonda consistently prevented...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.015(15.0%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.5¢ | $12.58K | 114.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45861 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 59279 | 2 |
View Market Depth
| Last trade - 11.49am 18/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |